New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The separation of benign from malignant mesothelial proliferations is crucial to patient care but is frequently morphologically difficult.Context.— To briefly review adjunctive tests claimed to be useful in this setting and to examine in detail 2 new tests: p16 fluorescence in situ hybridization (FISH) and BRCA1-associated protein 1 (BAP1) immunohistochemistry.Objective.— Literature review with emphasis on p16 FISH and BAP1 immunohistochemistry.Design.— Glucose transporter-1, p53, insulin-like growth factor 2 messenger RNA–binding protein 3 (IMP-3), desmin, and epithelial membrane antigen have all been claimed to mark either benign or malignant mesothelial processes, but in practice they at best provide statistical differences in large series of cases, without being useful in an individual case. Homozygous deletion of p16 by FISH or loss of BAP1 has only been reported in malignant mesotheliomas and not in benign mesothelial proliferations. BAP1 appears to be lost more frequently in epithelial than mixed or sarcomatous mesotheliomas. Homozygous deletion of p16 by FISH is seen in pleural epithelial, mixed, and sarcomatous mesotheliomas, but it is much less frequent in peritoneal mesothelioma. The major drawback to both these tests is limited sensitivity; moreover, failure to find p16 deletion or BAP1 loss does not make a mesothelial process benign.Results.— In the context of a mesothelial proliferation, the finding of homozygous deletion of p16 by FISH or loss of BAP1 by immunohistochemistry is, thus far, 100% specific for malignant mesothelioma. The limited sensitivity of each test may be improved to some extent by running both tests.Conclusions.—
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076 · cited 1×
“BAP1 somatic mutations appear to be common in mesotheliomas,(30) and, most important from the point of view of diagnosis, the presence of biallelic mutations in BAP1 determined by molecular analysis correlates with loss of immunohistochemical staining, while cells expressing at least 1 wild-type copy of BAP1 retain im…”
BackgroundCellular senescence and tumor suppressor gene p16
Rayess, H., Wang, M. B., & Srivatsan, E. S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27316 · Cited by 825 · cited 2×
“p16 is a tumor suppressor gene; the normal action of its gene product is to arrest the cell cycle in G1.(20,21) Conversely, the functional result of p16 deletion is enhanced cell proliferation.”
BackgroundBott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Minato, H., Kurose, N., Fukushima, M., Nojima, T., Usuda, K., Sagawa, M., Sakuma, T., Ooi, A., Matsumoto, I., Oda, M., et al. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcp5knl7qtellyi · Cited by 67 · cited 1×
“Reports that support or refute the specificity of EMA continue to be published.(6,7) We found that approximately 30% of patients with a diagnosis of atypical mesothelial hyperplasia and positive EMA staining were alive at 5 years after diagnosis.”
Background
Cited by
Husain, Colby, Ordóñez, Allen, Attanoos, Beasley, Butnor, Chirieac, Churg, Dacic, et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0124-ra · Cited by 619
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Self-citationERS/EACTS statement on the management of malignant pleural effusions
Bibby, A. C., Dorn, P., Psallidas, I., Porcel, J. M., Janssen, J., Froudarakis, M., Subotic, D., Astoul, P., Licht, P., Schmid, R., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00349-2018 · Cited by 316
Galateau Salle, F., Le Stang, N., Nicholson, A. G., Pissaloux, D., Churg, A., Klebe, S., Roggli, V. L., Tazelaar, H. D., Vignaud, J. M., Attanoos, R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.023 · Cited by 93
“When BAP1 was lost in the spindle cell component, it was considered as a decisive argument in favor of malignancy, and when retained it was considered indeterminate for malignancy.(24-29) p16 protein (clone E6H4) prediluted Ventana was considered positive (diffuse or focal heterogeneous nuclear staining) or negative (…”
Self-citationClinical Significance of Histologic Subtyping of Malignant Pleural Mesothelioma
Brcic, L., & Kern, I. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.38 · Cited by 77
“Based on this results, patients with ASS1 loss in 75% of tumor were included in a phase II/III study whose results should be soon published (75) It has been known that BAP-1 loss detected by immunohistochemistry is used as a proof of malignancy, and therefore in differentiation of reactive mesothelial proliferation ve…”
Method
Metadata
- Authors
- Churg, A., Sheffield, B. S., & Galateau-Salle, F.
- Venue
- Archives of Pathology & Laboratory Medicine
- Published
- 2015-08-19
- Volume
- 140
- Issue
- 4
- Pages
- 318-321
- ISSN
- 0003-9985 (ISSN-L)
- 1543-2165
- OpenAlex
- W1827919153
- Cited by
- 156
- References
- 4
- FWCI
- 14.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet? https://app.cochat.ai/papers/10.5858/arpa.2015-0240-sa
- The paper
- Churg, A., Sheffield, B. S., & Galateau-Salle, F. (2016). New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet? Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/arpa.2015-0240-sa
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.